In addition, there has been evidence of oncogenic drivers, such as EGFR mutation (10–15% NSCLC), BRAF mutation (approximately 7% NSCLC), ALK rearrangement (3–8% NSCLC), and ROS1 translocation (approximately 2% NSCLC), that confer sensitivity to tyrosine kinase inhibitors (TKIs) [2]. This evidence concerns the gene ALK and non-small cell lung carcinoma.